
About Autolus
Autolus is a publicly listed company based in London (United Kingdom) founded in 2015. Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. Autolus has raised $181.37 million across 5 funding rounds from investors including BioNTech, Blackstone and Syncona. The company has 647 employees. Its chief executive, as recorded, is Christian Martin Itin. Its website autolus.com draws about 22 thousand monthly visits. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is AUTOLUS LIMITED.
Company details
Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.
- Headquarters London, United Kingdom
- Employees 647
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website autolus.com
- Social LinkedIn
- Legal Name Autolus Therapeutics Plc Sponsored Adr
- Annual Revenue$75.56 M (USD)646.37as on Dec 31, 2025
- Net Profit-$288.2 M (USD)-30.55as on Dec 31, 2025
- EBITDA-$271.6 M (USD)-27.24as on Dec 31, 2025
- Total Equity Funding$181.37M (USD)
in 5 rounds
- Latest Funding Round$200M (USD), Post-IPO
Feb 2024
- InvestorsBioNTech
& 5 more
- Employee Count647
Funding Insights of Autolus
Autolus has successfully raised a total of $181.37M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $181.37M
- Total Rounds 5
- Last Round Post-IPO β $200M
- First Round $45.4M
(Jan 2015)
- Investors Count 6
All 5 funding rounds of Autolus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $200M | Post-IPO | β | β | |
| Nov 2021 | Post-IPO | β | β | ||
| Sep 2017 | $80M | Series C | β | Syncona | |
| Mar 2016 | $55.97M | Series B | β | β | |
| Jan 2015 | $45.4M | Series A | β | β |
6 investors in total: 6 institutional.
Investors in Autolus
Autolus has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Blackstone and Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | biontech.com | Mainz, Germany | |
Diversified investment portfolios are managed for clients by the firm. | 2014 | woodfordfunds.com | Swindon, United Kingdom |
Investor details for Autolus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Autolus
137 people are tracked at Autolus (62 in leadership, 75 in team); the tracked headcount is 647.
| Name | Role | Group |
|---|---|---|
Linda Catharina Bain | Non-Executive Director | Leadership |
Cynthia Marie Butitta | Independent Non-Executive Director | Leadership |
John Berriman | Non-Executive Director | Leadership |
Christian Martin Itin | CEO | Leadership |
Martin Pule | SVP, Founder & Chief Scientific Officer | Leadership |
Christopher Vann | SVP & Chief Operating Officer | Leadership |
Matthew N. | Associate Director Of Apheresis & Infusion Operations | Leadership |
Adam Cooper | Associate Director Of Production | Leadership |
Christian Lang | Senior Director, Strategic Center Engagement | Leadership |
Lindsay Luke | Vp, Centre Engagement & Alliance Management | Leadership |
Alexander Swan | Chief Human Resources Officer | Leadership |
Leila Mekkaoui | Director | Leadership |
Christopher Fisher | Director Material Sciences, Manufacturing Strategy And Technology | Leadership |
Marcos Giovannoni | Director, Production | Leadership |
Christian Itin | Chairman & CEO | Leadership |
Melia Loskill | Vice President Of Market Access | Leadership |
Austin Fisher | Vice President, Patient & Channel Access | Leadership |
Charles Skinner Bsc Aca | Senior Director, Group Financial Controller | Leadership |
Andrew Bolton | Associate Director, Production | Leadership |
Gerardo Santiago Toledo | Associate Director, Cell Process Development | Leadership |
117 more people are available in the full profile.
Complete people profiles for Autolus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Autolus
Autolus is a publicly listed company on the NASDAQ with ticker symbol AUTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2018
- Listed onFRA: 6A3A
- Listed entityAutolus Therapeutics Plc Sponsored ADR
- Exchange sectorHealth technology
- ISINUS05280R1005
- Share price$1.62 (-6.9% on the day) · 2026-10-13
- Market capitalisation$431.2M
- EPS (diluted, trailing year)$-1.05
- Volume (last session)2,420,302
Financials of Autolus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $75.6M | -$288.2M | -$271.6M |
| 2024 | $10.1M | -$220.8M | -$213.5M |
| 2023 | $1.7M | -$209.2M | -$189.2M |
| 2022 | $6.2M | -$148.8M | -$160.1M |
| 2021 | $1.5M | -$142.1M | -$156.6M |
Detailed financial statements for Autolus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Autolus
4 dated milestones of Autolus across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Autolus is founded.
- Funding First funding round of $45.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $200.0M.
Web traffic of Autolus
The website of Autolus (autolus.com) receives about 22K visits a month and ranks #1,467,054 among all websites worldwide, #1,917 in Biotechnology and Pharmaceuticals.
- Monthly visits22K
▲ 10.4% vs previous month
- Unique visitors6.6K
per month
- Global rank#1,467,054
among all websites
- Category rank#1,917
Health · Biotechnology and Pharmaceuticals
- Bounce rate56%
- Pages per visit1.6
- Average visit1 min 23 sec
- DevicesDesktop 59% Β· Mobile 41%
Websites whose visitors overlap most with Autolus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bioinformant.com | bioinformant.com | 100% | #761,820 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Autolus
Complete news archive for Autolus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Autolus
Autolus was founded in 2015.
Autolus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Christian Martin Itin is the CEO of Autolus, as recorded in our data.
Autolus is a funded company, having raised a total of $181.37M across 5 funding rounds to date. The company's 1st funding round was a Series A of $45.4M, raised on Jan 2015.
Autolus has 647 employees.
Annual revenue of Autolus is $75.56M as on Dec 31, 2025.
Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.
Yes, Autolus is publicly traded on NASDAQ under the ticker symbol AUTL.
Autolus has 6 investors. Key investors include BioNTech, Blackstone, Syncona, Arix Bioscience, and Woodford Investment Management.
Autolus operates through Autolus Limited.
